



Tetraphase Pharmaceuticals  
Investor Relations Department  
480 Arsenal Street, Suite 110  
Watertown, MA 02472  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: TTPH

Last Trade:	6.90
Trade Time:	4:00 PM ET Jul 25, 2017
Change:	-0.40 <span style="color: red;">↓</span> (-5.479%)
Day Range	6.77 - 7.32
52-Week Range	3.11 - 9.93
Volume	1,256,351


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

*Jul 25, 2017*

[Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections](#)

*Jun 5, 2017*

[Tetraphase Pharmaceuticals Announces Positive Phase 1 Single-Ascending Dose Data for Antibiotic Pipeline Candidates](#)

*May 30, 2017*

[Tetraphase Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference](#)

*May 22, 2017*

[Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017](#)

*May 4, 2017*

[Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights](#)

## Financials & Filings [\[ View all \]](#)

*Mar 13, 2017*

[Annual Report \(10-K\)](#)

*Apr 21, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 4, 2016*

[Quarterly Report \(10-Q\)](#)